As the HIV research community prepares to convene for the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 ...

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes. The National Comprehensive Cancer Network (NCCN) ...

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...

In the final episode, Assessing Long-Term Renal Outcomes and Kidney Failure Risk Reduction in IgA Nephropathy, the panelists ...

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health ...

Chomont is a Professor in the Department of Microbiology, Infectious Diseases, and Immunology at the Université de Montréal and a researcher at the CHUM Research Centre CROI 2026 highlights will ...

Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment.

Compensation reforms prohibit price- or rebate-linked PBM revenue in Part D, pushing flat service-fee models and broadly capturing affiliates such as rebate GPOs and aggregators. Reform priorities aim ...

A US-focused cohort study published in 2023 showed similar trends, with a higher AA incidence observed among women (range, ...

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting ...